
|Videos|March 24, 2016
Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian Cancer
Author(s)Ursula Matulonis, MD
Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.
Advertisement
Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer. Matulonis says the trials, dubbed NRG-GY004 and NRG-GY005, look at the combination of cediranib and olaparib in both platinum-sensitive and platinum-resistant recurrent ovarian cancer after a successful phase II looking at the combination against olaparib as a single agent.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















